Novo Nordisk’s Fiasp (insulin aspart injection) Receives the FDA’s Approval for use in Insulin Infusion Pumps to Treat Type 1 or Type 2 Diabetes

Novo Nordisk’s Fiasp (insulin aspart injection) Receives the FDA’s Approval for use in Insulin Infusion Pumps to Treat Type 1 or Type 2 Diabetes

Shots:

  • The US FDA has expanded the label for Fiasp (insulin aspart injection, 100 u/mL) to be used in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes
  • The label change is based on the onset 5 clinical study evaluating the efficacy and safety of Fiasp (SC) vs NovoLog used in insulin infusion pumps in adults with diabetes. Results demonstrated that Fiasp is well tolerated and effective in pumps releasing steady doses throughout the day and mealtime doses during meals
  • Fiasp is the first and only fast-acting mealtime insulin injection, administered at the beginning of a meal or within 20 minutes after starting a meal and has received FDA’s approval as an IV infusion or SC MDI in adults with diabetes

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Diabetes Daily